Seminars in Oncology
Volume 34, Issue 5 , Pages 418-424, October 2007

Recently Identified Colon Cancer Predispositions: MYH and MSH6 Mutations

  • Fay Kastrinos

      Affiliations

    • Division of Gastroenterology, Brigham and Women’s Hospital, Boston, MA.
    • Population Sciences Division, Dana-Farber Cancer Institute, Boston, MA.
  • ,
  • Sapna Syngal

      Affiliations

    • Division of Gastroenterology, Brigham and Women’s Hospital, Boston, MA.
    • Population Sciences Division, Dana-Farber Cancer Institute, Boston, MA.
    • Harvard Medical School, Boston, MA.
    • Corresponding Author InformationAddress correspondence to Sapna Syngal, MD, MPH, Dana-Farber Cancer Institute, 1 Jimmy Fund Way, SM 209, Boston, MA 02115.

published online 28 July 2007.

Single-gene germline mutations conferring a high lifetime risk of colorectal cancer (CRC) account for up to 6% of all CRC cases. The most widely studied monogenic colorectal cancer syndromes include familial adenomatous polyposis (FAP) and Lynch syndrome. However, additional syndromes continue to be defined and new predisposition genes are continuing to be identified. Most recently, MYH-associated polyposis (MAP) and an “atypical Lynch syndrome” related to the presence of MSH6 mutations have been linked to an increased risk of CRC. In this review, we summarize basic information related to these newly recognized gene mutations, including the accumulating data on the prevalence and penetrance of deleterious mutations, as well as the management options for identified carriers and their families. Recognizing these heritable syndromes is essential and predictive genetic testing will continue to transform the field of cancer risk assessment by offering the opportunity to focus on more precise risk management and cancer prevention.

To access this article, please choose from the options below

Login to an existing account or Register a new account.

  • Purchase this article for 31.50 USD (You must login/register to purchase this article)

    Online access for 24 hours. The PDF version can be downloaded as your permanent record.

  • Subscribe to this title

    Get unlimited online access to this article and all other articles in this title 24/7 for one year.

  • Claim access now

    For current subscribers with Society Membership or Account Number.

  • Visit SciVerse ScienceDirect to see if you have access via your institution.
 

PII: S0093-7754(07)00142-X

doi:10.1053/j.seminoncol.2007.07.005

Seminars in Oncology
Volume 34, Issue 5 , Pages 418-424, October 2007